|
|
Vaccine Detail
|
MUC1(T-antigen)-Pam3CSK4 lipoglycopeptide vaccine |
| Vaccine Information |
- Vaccine Name: MUC1(T-antigen)-Pam3CSK4 lipoglycopeptide vaccine
- Target Pathogen: Cancer
- Target Disease: Cancer
- Type: Conjugate vaccine
- Status: Research
- Host Species for Licensed Use: Mouse
- Antigen: MUC1 VNTR (20aa) (Kaiser et al., 2010)
- Immunization Route: subcutaneous injection
- Description: A fully synthetic self-adjuvanting vaccine composed of tumor-associated MUC1 glycopeptides from the tandem repeat region bearing T-antigen (vaccine 10), Tn-antigen (vaccine 9), or 2,6-sialyl-T-antigen (vaccine 11) side chains, covalently conjugated via an oligoethylene glycol spacer to the Pam3CSKKKK TLR2 agonist lipopeptide, synthesized by fragment condensation in 20–25% yield. Immunization of balb/c-J mice with vaccine 10 (T-antigen) with CFA/IFA elicited a specific humoral immune response in all three immunized mice by ELISA, though antiserum titers were lower than the corresponding MUC1-tetanus toxoid vaccine. Induced antibodies recognized the homologous T-antigen MUC1 glycopeptide 13a, unglycosylated MUC1 peptide 13b, and MUC1 glycopeptides bearing Tn-antigen (13c) or sialyl-Tn-antigen (13d) at the same glycosylation position, but failed to recognize MUC1 glycopeptides glycosylated at different positions (14, 15) or MUC4 peptide 16, indicating recognition dominated by peptide sequence and conformation over carbohydrate identity. Incomplete neutralization by free T-antigen MUC1 13a suggested Pam3Cys influence on B-cell epitope conformation. Immunization required Freund's adjuvant (Kaiser et al., 2010).
|
| Host Response |
|
|
| References |
Kaiser et al., 2010: Kaiser A, Gaidzik N, Becker T, Menge C, Groh K, Cai H, Li YM, Gerlitzki B, Schmitt E, Kunz H. Fully synthetic vaccines consisting of tumor-associated MUC1 glycopeptides and a lipopeptide ligand of the Toll-like receptor 2. Angewandte Chemie (International ed. in English). 2010; 49(21); 3688-3692. [PubMed: 20449837].
|
|
